附属公司易主上海医药,和黄医药逾44亿元剥离中药资产,加码ADC开发

时代财经
02 Jan

接近和黄医药的人士告诉时代财经,近几年的年报显示,和黄医药一直在寻找非核心业务的合作伙伴,无论是从战略还是从现金流的角度考量,公司都将剥离非核心资产,未来将更加聚焦和专注创新药方面的可持续发展。1月1日晚间,和黄医药(HCM.US;00013.HK)对外宣布,其旗下附属公司上海和黄药业有限公司(下称“上海和黄药业”)易主上海医药(601607.SH;02607.HK)。根据公告,和黄医药以6.08...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10